Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Asia Pacific Will Supplant US-Europe as Pharma Center

publication date: Aug 7, 2007
Findings of New PricewaterhouseCoopers Study A new PricewaterhouseCoopers study posits that Asia-Pacific countries will eventually be the center for global biopharma. The balance will migrate away from the US-Europe axis that currently drives the sector. Multinational corporations are investing money into China, India and Singapore, lured by the size of their markets as these large population countries become more affluent and demand western-style pharmaceuticals. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital